Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L
Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7PN, UK.
Epidemiol Infect. 2002 Dec;129(3):577-85. doi: 10.1017/s0950268802007902.
Hepatitis C virus (HCV) among injecting drug users (IDUs) is one of the European Union's (EU) major public health problems. This review examines the current state of knowledge regarding HCV among IDUs in EU countries. Studies published between January 1990 and December 2000, were identified through a computerized search (MEDLINE and EMBASE). Ninety-eight studies have reported prevalence for HCV among groups of IDUs in all EU countries except Luxembourg. The prevalence of anti-HCV ranged from 30 to 98%. Incidence rates ranged from 6.2 to 39.3 per 100 person years. This review provides a comprehensive examination of HCV infection among IDUs in the countries of the EU, and quite clearly demonstrates that the quality and epidemiological relevance of the studies published varies widely. Thus, the reported data may not reflect accurately the current or recent past prevalence of HCV among IDUs in the EU. A strategic approach to the surveillance of HCV among IDUs in the EU, utilizing robust and consistent methods, is required urgently.
注射吸毒者中的丙型肝炎病毒（HCV）是欧盟（EU）主要的公共卫生问题之一。本综述考察了欧盟国家注射吸毒者中丙型肝炎病毒的现有知识状况。通过计算机检索（MEDLINE和EMBASE）确定了1990年1月至2000年12月期间发表的研究。除卢森堡外，98项研究报告了所有欧盟国家注射吸毒者群体中丙型肝炎病毒的流行情况。抗-HCV的流行率在30%至98%之间。发病率在每100人年6.2至39.3之间。本综述全面考察了欧盟国家注射吸毒者中的丙型肝炎病毒感染情况，并且非常清楚地表明所发表研究的质量和流行病学相关性差异很大。因此，报告的数据可能无法准确反映欧盟注射吸毒者中丙型肝炎病毒目前或近期的流行情况。迫切需要采用强有力且一致的方法，对欧盟注射吸毒者中的丙型肝炎病毒进行监测的战略方针。
